CD4 and myeloid sarcoma: However, as stated above, a recent study has shown restored regulatory capacity of CD4+CD25high cells from patients, equivalent to healthy controls three and four years post treatment indicating a long-term rebalancing of immune-tolerance networks [56], at least for MS-related autoimmune responses.